Blueprint’s latest approval for Ayvakit sets up clash with NovartisBlueprint Medicines has claimed its second FDA approval for Ayvakit, getting the nod for advanced systemic mastocytosis (SM), Share XBlueprint’s latest approval for Ayvakit sets up clash with Novartishttps://pharmaphorum.com/news/blueprints-latest-approval-for-ayvakit-sets-up-clash-with-novartis/
After FDA approval, Alkermes plans soft launch for antipsychotic LybalviThe FDA approval of Alkermes’ new antipsychotic drug Lybalvi couldn’t have gone any better for the company, but Share XAfter FDA approval, Alkermes plans soft launch for antipsychotic Lybalvihttps://pharmaphorum.com/news/after-fda-approval-alkermes-plans-soft-launch-for-antipsychotic-lybalvi/
FDA hands Cassiopea its first approval, for acne drug WinleviItalian biotech Cassiopea has won US approval for Winlevi, a topical therapy it says is the first new Share XFDA hands Cassiopea its first approval, for acne drug Winlevihttps://pharmaphorum.com/news/fda-hands-cassiopea-its-first-approval-for-acne-drug-winlevi/
ViiV gets FDA nod for Rukobia drug for older HIV patientsThe FDA has approved Rukobia, a first-in-class drug from ViiV Healthcare intended for older people with HIV, who Share XViiV gets FDA nod for Rukobia drug for older HIV patientshttps://pharmaphorum.com/news/viiv-gets-fda-nod-for-rukobia-drug-for-older-hiv-patients/
AZ claims FDA okay for Brilinta in coronary artery disease patientsAstraZeneca’s anti-platelet drug Brilinta has been cleared in the US for a major new indication, preventing a first Share XAZ claims FDA okay for Brilinta in coronary artery disease patientshttps://pharmaphorum.com/news/az-claims-fda-okay-for-brilinta-in-coronary-artery-disease-patients/
BMS gets FDA nod for ozanimod, but launch will be delayedBristol-Myers Squibb’s multiple sclerosis therapy ozanimod has been approved by the FDA right on schedule, but the company Share XBMS gets FDA nod for ozanimod, but launch will be delayedhttps://pharmaphorum.com/news/bms-gets-fda-nod-for-ozanimod-but-launch-will-be-delayed/
Celgene scores FDA okay for thalassaemia drug ReblozylThe FDA has approved Celgene and Acceleron’s Reblozyl, which is the first drug to be approved in the Share XCelgene scores FDA okay for thalassaemia drug Reblozylhttps://pharmaphorum.com/news/celgene-scores-fda-okay-for-thalassaemia-drug-reblozyl/
Biogen bags FDA okay for Tecfidera follow-up VumerityBiogen’s multiple sclerosis franchise has been handed a boost with the US approval of Vumerity, a follow-up to Share XBiogen bags FDA okay for Tecfidera follow-up Vumerityhttps://pharmaphorum.com/news/biogen-fda-tecfidera-vumerity-ms/
Merck, Eisai get triple approvals for Keytruda/Lenvima combinationThe combination of Merck & Co’s Keytruda with targeted drug Lenvima has been approved for endometrial cancer in Share XMerck, Eisai get triple approvals for Keytruda/Lenvima combinationhttps://pharmaphorum.com/news/merck-eisai-get-triple-approvals-for-keytruda-lenvima-combination/
